FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, namely to a polypeptide which activates the epithelial ion channels. The presented invention can be used for producing a drug preparation for diseases related to pulmonary function, such as oedemas. The presented polypeptide is an amino acid sequence of a region from valine Val(91) to glycine Gly(121) of the mature human tumour necrosis factor, or a functionally active fragment thereof, provided the polypeptide or fragment thereof comprises at least an amino acid sequence of a region from lysine Lys(98) to glutamic acid Glu(116), wherein cysteine Cys(101) is substituted by glycine, and an amide bond is formed between an amino group of a side chain of lysine Lys(98) and a carboxyl group of a side chain of glutamic acid Glu(116).
EFFECT: presented invention enables activating the epithelial ion channels and improves the pulmonary function.
5 cl, 6 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
